- Home
- URGN vs NWBI Comparison
URGN vs NWBI Comparison
Compare URGN & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | URGN | NWBI |
|---|---|---|
| Founded | 2004 | 1896 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2016 | 2009 |
Fundamental Metrics
Financial Performance| Metric | URGN | NWBI |
|---|---|---|
| Price | $25.99 | $15.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $60.71 | $16.43 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-04-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 5.29% |
| EPS Growth | N/A | ★ 16.46 |
| EPS | N/A | ★ 1.05 |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $190.44 | $11.47 |
| Revenue Next Year | $69.25 | $4.86 |
| P/E Ratio | ★ N/A | $14.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.50 | $11.25 |
| 52 Week High | $50.81 | $16.16 |
Technical Indicators
Market Signals| Indicator | URGN | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 27.59 | 46.13 |
| Support Level | $23.51 | $14.49 |
| Resistance Level | $27.76 | $15.78 |
| Average True Range (ATR) | 2.05 | 0.31 |
| MACD | -0.35 | -0.04 |
| Stochastic Oscillator | 13.91 | 7.58 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.